Previous Research has shown SelenoExcell(R) Supplementation to reduce Lung, Colon and Prostate Cancers by as much as 63%

FRESNO, Calif., Oct. 29 (SEND2PRESS NEWSWIRE) — Cypress Systems, Inc, a Fresno CA based biotechnology company, emphasizes that the SELECT TRIAL results – that were announced yesterday – used a form of selenium known as selenomethionine. The SELECT TRIAL found no effects of either selenomethionine or vitamin E on the incidence of prostate cancer. See Related Website at www.cypsystems.com .

The results of the SELECT TRIAL are consistent with previous animal studies. For example, Dr. David McCormick at the Experimental Toxicology and Carcinogenesis Division, IIT Research Institute in Chicago found no effects with selenomethionine supplementation on the prevention of prostate cancer in rats (Eur Urol 1999;35:464-467).

Such negative findings have not been observed for other forms of selenium. For example, research at Purdue University found SelenoExcell(R) High-Selenium Yeast to be more effective than selenomethionine in the reducing DNA damage in canine prostate cells (Waters et al, J. Natl Cancer Inst (2003); 95:237-240). Researchers at the University of Arizona and Cornell University reported in the Journal of American Medical Association (Clark et al, JAMA, Dec. 25, 1996-vol. 276, No.24).) that regular use of 200 micrograms per day of selenium in the form of SelenoExcell(R) reduced the incidences of lung, colon, and prostate cancers by 50-63%. Researchers at the Penn State University Cancer Institute found that supplementation with SelenoExcell(R), reduced serum PSA levels, a risk indicator for prostate cancer (El-Bayoumy et al, Cancer Epidemiology Vol. 11, 1459-1465, Nov., 2002). References to these and other studies can be found at the website, www.cypsystems.com – under the research matrix “Cancer” section of the home page.

Paul A. Willis, CEO & President of Cypress Systems, Inc. stated that “Clearly we believe that the SELECT TRIAL should have included the standardized high-selenium yeast, which has been found effective in reducing cancer risk in animal studies and human clinical trials.” High-selenium yeast is different from selenomethionine. It contains several different forms of organically-bound selenium in addition to selenomethionine.

According to Dr. Mark Whitacre, Cypress Systems’ COO, “We suspect that the advantage of SelenoExcell(R) High-Selenium Yeast lies in its content of multiple forms of selenium, including some that are more direct acting in anti-carcinogenesis.”

All trademarks are property of their respective owners.

News issued by: Cypress Systems, Inc.

Cypress Systems, Inc.

Original Image: https://www.send2press.com/mediaboom/08-0101-Send2Press_72dpi.jpg

# # #

Original Story ID: (4432) :: 2008-10-1029-001

Original Keywords: Cypress Systems, Inc., SELECT TRIAL results, high-selenium yeast, SelenoExcell, more effective than selenomethionine in the reducing DNA damage in canine prostate cells, human clinical trials, CEO Paul A. Willis, Dr. Mark Whitacre, Experimental Toxicology and Carcinogenesis Division, IIT Research Institute Cypress Systems, Inc.

News Source: Cypress Systems, Inc.